Cited by 476Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The importance of tau phosphorylation for neurodegenerative diseases

Open access
Noble, Wendy, Hanger, Diane P., Miller, Christopher C. J., Lovestone, Simon·2013·Frontiers in Neurology

Abstract

Fibrillar deposits of highly phosphorylated tau are a key pathological feature of several neurodegenerative tauopathies including Alzheimer's disease (AD) and some frontotemporal dementias. Increasing evidence suggests that the presence of these end-stage neurofibrillary lesions do not cause neuronal loss, but rather that alterations to soluble tau proteins induce neurodegeneration. In particular, aberrant tau phosphorylation is acknowledged to be a key disease process, influencing tau structure, distribution, and function in neurons. Although typically described as a cytosolic protein that associates with microtubules and regulates axonal transport, several additional functions of tau have recently been demonstrated, including roles in DNA stabilization, and synaptic function. Most recently, studies examining the trans-synaptic spread of tau pathology in disease models have suggested a potential role for extracellular tau in cell signaling pathways intrinsic to neurodegeneration. Here we review the evidence showing that tau phosphorylation plays a key role in neurodegenerative tauopathies. We also comment on the tractability of altering phosphorylation-dependent tau functions for therapeutic intervention in AD and related disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2013.00083

Cites

170 of 171 references verified1 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tau phosphorylation is likely to promote axonal degeneration and eventual neuronal death.

    “Because tau phosphorylation is likely to promote axonal degeneration and eventual neuronal death, we analyzed cell death within the brains of our 5xFAD models.”
  • Hyperphosphorylation of tau is a marker of progressive Alzheimer's disease in both humans and mice; its incidence increases as disease progresses and leads to microtubule de-stabilization and failure of the microtubule architecture, especially within neuronal axons.

    “A marker of progressive AD in both humans and mice is the hyperphosphorylation of the microtubule-stabilizing protein tau. The incidence of tau phosphorylation increases as disease progresses and leads to microtubule de-stabilization and failure of the microtubule architecture, especially within neuronal axons (Frost et al., 2015; Gong and Iqbal, 2008; Noble et al., 2013).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S.
Affiliations
King's College London (GB)
Corresponding author
  • Noble, Wendy
  • Lovestone, Simon
Venue
Frontiers in Neurology
Published
2013
Volume
4
Pages
83-83
ISSN
1664-2295 (ISSN-L)
OpenAlex
W2011634611
Cited by
475
References
169
Citations by year
2026: 27 · 2025: 51 · 2024: 56 · 2023: 58 · 2022: 56 · 2021: 56 · 2020: 35 · 2019: 24 · 2018: 28 · 2017: 26 · 2016: 17 · 2015: 19 · 2014: 17 · 2013: 4
FWCI
13.23
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • Wellcome Trust
  • National Institute for Health and Care Research (NF-SI-0512-10053)
  • National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/K500343/1)
  • Directorate for Biological Sciences
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
tau phosphorylation, tauopathy, Alzheimer's disease, frontotemporal dementia, neurofibrillary tangles, soluble tau, trans-synaptic spread, extracellular tau, synaptic function, DNA stabilization, axonal transport, neurodegeneration, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review